Overview and Scope
Post-traumatic stress disorder therapeutics refers to therapeutics used to treat post-traumatic stress disorder (PTSD), a mental health condition triggered by either experiencing it or witnessing it. Post-traumatic stress disorder treatment helps to improve patients thinking power, changes in physical activity & regain a sense of control over life. The mode of treatment applied for post-traumatic stress disorder includes medication, therapies, self-care & nutrition.
Sizing and Forecast
The post-traumatic stress disorder therapeutics market size has grown strongly in recent years. It will grow from $1.09 billion in 2023 to $1.15 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increased awareness, trauma incidence, government initiatives, advancements in diagnostic tools, stigma reduction, psychological support programs, veteran healthcare focus..
The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.35 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to expanded access to mental health services, government mental health policies, biological and neurological research, ptsd in non-military populations, crisis response planning.. Major trends in the forecast period include integration of digital therapeutics, advancements in pharmacological treatments, neurostimulation and brain stimulation techniques, psychedelic-assisted therapy, collaborative research initiatives..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/post-traumatic-stress-disorder-therapeutics-global-market-report
Segmentation & Regional Insights
The post-traumatic stress disorder therapeutics market covered in this report is segmented –
1) By Drug Class: Antidepressants, Anti-Anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics Or Second Generation Antipsychotics (SGOs), Beta-Blockers, Other Classes
2) By Age Group: Pediartic, Geriatric, Adult
3) By End User: Mental Health Center, Hospitals, Outpaitent Clinics, Other End Users
North America was the largest region in the post-traumatic stress disorder therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=9214&type=smp
Major Driver Impacting Market Growth
The rise in the burden of post-traumatic stress disorder (PTSD) cases across the globe are expected to propel the growth of the post-traumatic stress disorder therapeutics market going forward. Post-traumatic stress disorder refers to a disorder that develops in people who have experienced a scary, shocking, or dangerous event. Post-traumatic stress disorder treatment such as psychotherapy and medication can help to regain a sense of control over their life. For instance, according to the United States Department of Veterans Affairs, a US-based government department, nearly 8 million Americans are suffering from PTSD condition in 2021. Hence the rise in the burden of post-traumatic stress disorder (PTSD) cases is driving the growth of the post-traumatic stress disorder therapeutics market.
Key Industry Players
Major companies operating in the post-traumatic stress disorder therapeutics market report are Novartis AG, Pfizer Inc., GlaxoSmithKline PLC, Bionomics Limited, Apotex Inc., Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, Behavioral Health Network Inc., AstraZeneca PLC, Prometheon Pharma LLC, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Addex Therapeutics Ltd., Stella Center, Neurovation Labs Inc., Equip Global Pte Ltd., Compass Pathways PLC, Boehringer Ingelheim International GmbH, Halucenex Life Sciences Inc., Bionorica SE, MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Amgen Inc., Biogen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Industries Limited, Strategic Behavioral Health, Jazz Pharmaceuticals plc .
The post-traumatic stress disorder therapeutics market report table of contents includes:
1. Executive Summary
2. Post-Traumatic Stress Disorder Therapeutics Market Characteristics
3. Post-Traumatic Stress Disorder Therapeutics Market Trends And Strategies
4. Post-Traumatic Stress Disorder Therapeutics Market – Macro Economic Scenario
5. Global Post-Traumatic Stress Disorder Therapeutics Market Size and Growth
.
.
.
31. Global Post-Traumatic Stress Disorder Therapeutics Market Competitive Benchmarking
32. Global Post-Traumatic Stress Disorder Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Post-Traumatic Stress Disorder Therapeutics Market
34. Post-Traumatic Stress Disorder Therapeutics Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
